Trials / Completed
CompletedNCT00048451
Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 68 (planned)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | paricalcitol |
Timeline
- Start date
- 2002-02-01
- First posted
- 2002-11-04
- Last updated
- 2006-08-02
Locations
19 sites across 2 countries: United States, Poland
Source: ClinicalTrials.gov record NCT00048451. Inclusion in this directory is not an endorsement.